首页>Cancer chemotherapy and pharmacology.>Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab
作者单位：Department of Oncohematology,Centre Hospitalier Universitaire Grenoble-Alpes[1]Oncology Hematology and Cell Therapy Department,French National Agency for Safety of Medicines and[2]
换一批
